EMvision Medical Devices Ltd. (AU:EMV) has released an update.
EMVision Medical Devices Ltd has secured a strategic $15.28 million investment from Keysight Technologies to support the commercialization of its emu™ brain scanner, with market entry targeted for the next year. The device has shown promising results in a Stage 2 clinical trial, demonstrating strong AI performance in acute stroke diagnosis within an average scan time of 5.5 minutes. With cash reserves of $21.35 million and ongoing preparations for FDA pre-submission, EMVision is well-positioned for its next phase of clinical trials and the production of devices for U.S. stroke centers.
For further insights into AU:EMV stock, check out TipRanks’ Stock Analysis page.
